Biotech Values

[Whalatane]

Thx but all the FXR agonists I've looked at, record some elevations in ALT/AST and issues with pruritus .

These may be small numbers per trial ie less then 5% in P 2 trials ....but you ramp up larger numbers for a pivotal trial and you'll probably see more extremes.

Dew ...my wife was tangentially associated with Omonty for dialysis patients . Very small warning signs early on but drug was approved . Her hospital declined to use it but Da Vita I believe started using it until the first fatality after about the 20,000 applications.

My pt ...I think NASH drugs will need to be " very clean " to get FDA approval
JMO

Kiwi